ABBV Stock Recent News
ABBV LATEST HEADLINES
AbbVie has transitioned beyond Humira's exclusivity loss, with strong growth from Skyrizi and Rinvoq, targeting $27 billion in sales by 2027. The stock has surged to $200, now trading at 16x 2025 EPS targets, making it less of a bargain. AbbVie's dividend yield is 3.1%, with a potential hike to 3.3% in October, but debt remains high at over $60 billion.
JUVÉDERM® VOLUMA® XC is the One and Only Hyaluronic Acid Dermal Filler Indicated to Treat Cheeks, Chin, and Now Moderate to Severe Temple Hollowing1,2 Only Allergan Aesthetics, the Makers of BOTOX® Cosmetic (onabotulinumtoxinA), has FDA-Approved Injectables to Treat More Than 90% of the Face2-8 IRVINE, Calif. , Oct. 2, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple hollowing.
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
NORTH CHICAGO, Ill. , Oct. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens.
AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
The Investment Committee give you their top stocks to watch for the second half.
- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. - Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239).
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.